Literature DB >> 28861758

Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Hikmat Abdel-Razeq1, Asem Mansour2.   

Abstract

Patients with cancer are at a much higher risk of thromboembolic events. Such events are occasionally associated with significant complications that can negatively affect patients' quality of life. Thromboprophylaxis is widely practiced, but much of the emphasis is given for those admitted with acute medical illnesses or following major surgical procedures. However, a significant percentage of thrombotic events encountered in routine clinical practice are among ambulatory patients where current guidelines do not recommend routine thromboprophylaxis.

Entities:  

Keywords:  Ambulatory; Cancer; Embolism; Thromboprophylaxis

Mesh:

Year:  2017        PMID: 28861758     DOI: 10.1007/s11239-017-1542-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  45 in total

1.  Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?

Authors:  Thein Hlaing Oo
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

2.  Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax!

Authors:  Hikmat Abdel-Razeq; Faisal Albadainah; Shadi Hijjawi; Asem Mansour; Imad Treish
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

Authors:  Alok A Khorana; Charles W Francis; Nicole M Kuderer; Marc Carrier; Thomas L Ortel; Ted Wun; Deborah Rubens; Susan Hobbs; Renuka Iyer; Derick Peterson; Andrea Baran; Katherine Kaproth-Joslin; Gary H Lyman
Journal:  Thromb Res       Date:  2017-01-26       Impact factor: 3.944

4.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors:  A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

5.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

6.  Prediction of venous thromboembolism in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Christine Marosi; Alexandru-Laurentiu Chiriac; Rainer Vormittag; Ralph Simanek; Peter Quehenberger; Christoph Zielinski; Ingrid Pabinger
Journal:  Blood       Date:  2010-09-09       Impact factor: 22.113

7.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

Review 8.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

9.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316

View more
  5 in total

Review 1.  Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.

Authors:  Cristhiam M Rojas-Hernandez; Thein Hlaing Oo
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

2.  The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Hikmat Abdel-Razeq; Mohammad Ma'koseh; Asem Mansour; Rayan Bater; Rula Amarin; Alaa Abufara; Khalid Halahleh; Mohammad Manassra; Mohammad Alrwashdeh; Mohammad Almomani; Mais Zmaily
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

3.  The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients.

Authors:  Hikmat Abdel-Razeq; Mohammad Ma'koseh; Rashid Abdel-Razeq; Rula Amarin; Alaa Abufara; Razan Mansour; Mohammad Manasrah; Mohammad Al-Rwashdeh; Rayan Bater
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

4.  Predictors of Venous Thromboembolism in Patients With Testicular Germ Cell Tumors: A Retrospective Study.

Authors:  Hikmat Abdel-Razeq; Faris Tamimi; Rashid Abdel-Razeq; Samer Salah; Zaid Omari; Osama Salama; Alaa Abufara; Abdalla Al-Tell; Hanna Qahoush; Ahmad Nasman; Ayat Taqash; Yazan Alhalaseh; Rayan Bater
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Patterns and predictors of thromboembolic events among patients with gastric cancer.

Authors:  Hikmat Abdel-Razeq; Rawan Mustafa; Baha' Sharaf; Abdallah Al-Tell; Dina Braik; Khaled Ashouri; Zaid Omari; Razan Mansour; Jamil Qarqash; Hanin Shaqboua; Saba Jaradat; Kholoud Al-Qasem; Rayan Bater
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.